Laurène Meyniel-Schicklin, Jérôme Amaudrut, Pierre Mallinjoud, Fabrice Guillier, Philippe E Mangeot, Laetitia Lines, Anne Aublin-Gex, Caroline Scholtes, Claire Punginelli, Stéphane Joly, Florence Vasseur, Evelyne Manet, Henri Gruffat, Thomas Henry, Farès Halitim, Jean-Laurent Paparin, Peter Machin, Raphaël Darteil, Diane Sampson, Ivan Mikaelian, Lydie Lane, Vincent Navratil, Marie-Pierre Golinelli-Cohen, Fabiola Terzi, Patrice André, Vincent Lotteau, Jacky Vonderscher, Eric C Meldrum, Benoit de Chassey
We present a drug design strategy based on structural knowledge of protein-protein interfaces selected through virus-host coevolution and translated into highly potential small molecules. This approach is grounded on Vinland, the most comprehensive atlas of virus-human protein-protein interactions with annotation of interacting domains. From this inspiration, we identified small viral protein domains responsible for interaction with human proteins. These peptides form a library of new chemical entities used to screen for replication modulators of several pathogens...
January 30, 2024: Proceedings of the National Academy of Sciences of the United States of America